Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer.
Marco TagliamentoAlessandra GennariMatteo LambertiniRamón SalazarNadia HarbeckLucia Del MastroJuan AguilarMark BowerRachel SharkeyAlessia Dalla PriaAndrea PlajaAmanda JacksonJasmine HandfordAilsa Sita-LumsdenClara Martinez-VilaMarta MatasAna Miguel RodriguezBruno VincenziGiuseppe ToniniAlexia BertuzziJoan BrunetPaolo PedrazzoliFrancesca D'AvanzoFederica BielloAlasdair SinclairAlvin J X LeeSabrina RossiGianpiero RizzoOriol MirallasIsabel PimentelMaria IglesiasAna Sanchez de TorreAnnalisa GuidaRossana BerardiAlberto ZambelliCarlo TondiniMarco FilettiFrancesca MazzoniUma MukherjeeNikolaos DiamantisMaria Concetta FargnoliAvinash AujayebAleix PratMichela LibertiniSalvatore GrisantiMaura RossiFederica ZorattoDaniele GeneraliCristina SauraGary H LymanNicole M KudererDavid James PinatoAlessio Cortellininull nullPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Our findings highlight a consistent reduction of COVID-19 severity in patients with breast cancer during the Omicron outbreak in Europe. We also demonstrate that even in this population, a complete severe acute respiratory syndrome coronavirus 2 vaccination course is a strong determinant of improved morbidity and mortality from COVID-19.